A Prospective, Observational Study on Real-world Treatment Patterns of cabazitaxel (CBZ) in Ptients (pts) with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Trial Profile

A Prospective, Observational Study on Real-world Treatment Patterns of cabazitaxel (CBZ) in Ptients (pts) with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2018

At a glance

  • Drugs Cabazitaxel (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CAPRISTANA
  • Most Recent Events

    • 21 May 2018 Results (n=189) assessing health-related quality of life effects, presented at the 113th Annual Meeting of the American Urological Association.
    • 21 May 2018 Results (n=189) assessing the effectiveness and safety presented at the 113th Annual Meeting of the American Urological Association
    • 13 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top